111 / 119
110
Diretrizes AMB
treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol
Venereol. 2013 Dec;27(12):1535-45. PubMed PMID: 23279003.
28. Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO,
Schenkel B, Guzzo C, Li S, Papp KA. Long-term efficacy of ustekinumab
in patients with moderate-to-severe psoriasis: results from the PHOENIX
1 trial through up to 3 years. Br J Dermatol. 2012 Apr;166(4):861-72.
PubMed PMID: 22356258.
29. Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger
GG. Ustekinumab improves health-related quality of life in patients with